|
|
|
|
|
|
by refurb
1588 days ago
|
|
|
Yup, as someone who had some experience in the industry, this screams naivety. Generic drugs are pumped out for pennies a pill by a pre-existing infrastructure across the globe. Mark will be buying from them, not spending billions trying to replicate manufacturing plants and FDA agreements. In essence it’s a cash-only pharmacy for cheap generic drugs - not that different than what Walmart and Target do with their $4/month prescription drug program. Big pharma won’t give a shit because Mark can’t make his own generic versions due to IP. He might make a difference for those weird edge cases like Daraprim (sp?) where the market is so small, supply is constrained, so mark ups are huge. But those are weird edge cases that don’t last long. |
|
|
Of course there's no IP protection; that's the definition of "generic." But that doesn't mean big pharma won't care. 20 years ago they might not have cared. Nowadays big pharma has learned how to game the generics industry to become sole-source generic providers and set prices as high as they wish, even without IP protection. It's this abuse of the generic marketplace that Cuban seems to be taking on.